CAPLIPOINT:NSE-Caplin Point Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSE

Last Closing Price

INR 575.95

Change

+23.70 (+4.29)%

Market Cap

INR 41.82B

Volume

0.28M

Average Target Price

INR 556.67 (-3.35%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Caplin Point Laboratories Limited develops, manufactures, markets, and exports generic pharmaceutical formulations and branded generic products in India and internationally. It provides tablets, capsules, vials, ophthalmic products, liquid orals, soft gel capsules, ointments, creams and gels, powder for injections, suppositories and ovules, dermo cosmetics, surgicals and disposables, pre-mix bag formulations, inhalers and sprays, IV infusion products, dry syrups, topicals, and other products, as well as liquid, lyophilized, and pre-filled injection syringes. The company also operates QueTenX, an e-commerce website. Caplin Point Laboratories Limited was founded in 1990 and is based in Chennai, India. Address: Ashvich Tower, Chennai, India, 600096

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+20.45 (+4.18%)

INR1,174.83B 160.86 32.48
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+17.65 (+0.35%)

INR847.61B 44.75 26.36
DIVISLAB:NSE Divi's Laboratories Limited

+36.40 (+1.19%)

INR812.53B 50.23 34.27
LUPIN:NSE Lupin Limited

+10.05 (+1.01%)

INR452.63B 49.28 27.33
AUROPHARMA:NSE Aurobindo Pharma Limited

+28.60 (+3.70%)

INR452.40B 15.36 9.59
CADILAHC:NSE Cadila Healthcare Limited

+5.10 (+1.32%)

INR394.39B 29.06 16.74
ALKEM:NSE Alkem Laboratories Limited

-26.90 (-0.96%)

INR335.06B 24.10 18.33
IPCALAB:NSE Ipca Laboratories Limited

+11.00 (+0.53%)

INR261.69B 28.38 19.52
APLLTD:NSE Alembic Pharmaceuticals Limite..

+30.50 (+3.19%)

INR188.56B 17.42 14.41
NATCOPHARM:NSE NATCO Pharma Limited

+51.85 (+5.85%)

INR161.59B 35.29 23.75

ETFs Containing CAPLIPOINT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 95.50% 73% C 94% A
Dividend Return 0.14% 13% F 9% F
Total Return 95.64% 73% C 94% A
Trailing 12 Months  
Capital Gain 35.77% 27% F 80% B-
Dividend Return 0.09% 12% F 5% F
Total Return 35.87% 27% F 80% B-
Trailing 5 Years  
Capital Gain 99.67% 73% C 82% B-
Dividend Return 2.88% 59% F 29% F
Total Return 102.55% 73% C 82% B-
Average Annual (5 Year Horizon)  
Capital Gain 26.68% N/A N/A 85% B
Dividend Return 0.43% N/A N/A 31% F
Total Return 27.11% N/A N/A 85% B
Risk Return Profile  
Volatility (Standard Deviation) 69.44% N/A N/A 16% F
Risk Adjusted Return 39.04% N/A N/A 77% C+
Market Capitalization 41.82B 60% D- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.64 70% C- 44% F
Price/Book Ratio 4.66 38% F 14% F
Price / Cash Flow Ratio 93.60 8% F 2% F
EV/EBITDA 12.74 63% D 40% F
Management Effectiveness  
Return on Equity 27.06% 96% A 94% A
Return on Invested Capital 21.52% 97% A+ 93% A
Return on Assets 15.29% 98% A+ 98% A+
Debt to Equity Ratio 0.00% 88% B+ 90% A-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.75 56% F 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.